AI assistant
aTYR PHARMA INC — Director's Dealing 2015
May 6, 2015
34337_dirs_2015-05-06_6f8f0de6-9410-465d-a941-2aa27248634f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: aTYR PHARMA INC (LIFE)
CIK: 0001339970
Period of Report: 2015-05-06
Reporting Person: AKKARAJU SRINIVAS (Director, 10% Owner)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Series E Redeemable Convertible Preferred Stock | $ | Common Stock (14968722) | Indirect | ||
| Stock Option (right to buy) | $9.15 | 2025-04-02 | Common Stock (12572) | Direct |
Footnotes
F1: The aggregate number of shares of Issuer's Preferred Stock held by the Reporting Person converts into Common Stock immediately prior to the closing of the Issuer's initial public offering and has no expiration date. The shares convert into Common stock on a 1-for-9.6814 basis.
F2: These shares are owned directly by Sofinnova Venture Partners IX, L.P. ("SVP IX"). The general partner of SVP IX is Sofinnova Management IX, L.L.C. ("SM IX"). The managing members of SM IX, Dr. James I. Healy, Michael F. Powell, Ph.D., Dr. Srinivas Akkaraju, and Dr. Anand Mehra are deemed to have voting and dispositive power over the shares and may be deemed to beneficially own certain shares held by SM IX. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for Section 16 or any other purpose.
F3: The shares subject to this option shall vest and become exercisable in 36 equal monthly installments beginning on 3/31/2015. The shares subject to this option are early exercisable subject to the Issuer's right of repurchase, which right of repurchase lapses in accordance with the vesting schedule.